Regulators Have Ways To Address Drug Affordability, EMA Officials Say
This article was originally published in The Pink Sheet Daily
Executive Summary
Regulators can contribute to sustainable drug pricing by approving biosimilars quickly, encouraging drug trials that measure value and taking other actions, European Medicines Agency officials say in an op-ed published in the New England Journal of Medicine.